|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:battle
|
|
gptkbp:awards
|
Various industry awards
|
|
gptkbp:ceo
|
Gal Cohen
|
|
gptkbp:clinical_trial
|
gptkb:battle
Ongoing
Burn treatment
Chronic wound management
|
|
gptkbp:collaborations
|
Academic institutions
|
|
gptkbp:community_engagement
|
gptkb:battle
|
|
gptkbp:customer_base
|
Healthcare providers
Hospitals
Clinics
|
|
gptkbp:employees
|
50-100
|
|
gptkbp:financial_performance
|
gptkb:Annual_reports
Quarterly reports
|
|
gptkbp:focus
|
Wound care
|
|
gptkbp:founded
|
gptkb:2001
|
|
gptkbp:future_plans
|
Increase market share
Expand product line
Enhance R& D capabilities
|
|
gptkbp:global_presence
|
gptkb:battle
|
|
gptkbp:headquarters
|
Ness Ziona, Israel
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Medi Wound USA, Inc.
|
|
gptkbp:industry
|
gptkb:Company
|
|
gptkbp:invention
|
Multiple patents
|
|
gptkbp:investment
|
gptkb:Europe
gptkb:North_America
Institutional investors
Venture capital
|
|
gptkbp:marketing_strategy
|
Direct sales
Distributors
|
|
gptkbp:mission
|
Innovative wound care solutions
|
|
gptkbp:partnerships
|
Research institutions
Various healthcare organizations
|
|
gptkbp:products
|
gptkb:Nexo_Brid
Ongoing
Eschar Ex
|
|
gptkbp:regulatory_compliance
|
gptkb:battle
FDA approved
|
|
gptkbp:research_and_development
|
gptkb:battle
|
|
gptkbp:subsidiary
|
gptkb:Medi_Wound_Ltd.
|
|
gptkbp:supply_chain
|
Global supply chain
|
|
gptkbp:sustainability_initiatives
|
gptkb:battle
|
|
gptkbp:symbol
|
MDWD
|
|
gptkbp:technology
|
Enzymatic debridement
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:training
|
gptkb:battle
|
|
gptkbp:type
|
gptkb:football_club
|
|
gptkbp:vision
|
Leader in wound care
|
|
gptkbp:website
|
www.mediwound.com
|
|
gptkbp:bfsParent
|
gptkb:Medi_Wound_Ltd.
|
|
gptkbp:bfsLayer
|
3
|